Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mendes

Showing results (261-270 of 473) with videos related to

Pageof 48
Sort By:
Public Health Reports (Washington, D.C. : 1974)|November 1, 1990
Training health professionals and lay volunteers to deliver cholesterol screening and education programsL A Linnan, K M Gans, M L Hixson, et al.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas|August 20, 2010
Lipopolysaccharide-induced expression of cell surface receptors and cell activation of neutrophils and monocytes in whole human bloodN E Gomes, M K C Brunialti, M E Mendes, et al.
Regulatory Toxicology and Pharmacology : RTP|July 30, 2011
Factors affecting exposure to nicotine and carbon monoxide in adult cigarette smokersRaheema Muhammad-Kah, Qiwei Liang, Kimberly Frost-Pineda, et al.
Journal of Global Antimicrobial Resistance|December 7, 2020
Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by speciesHelio S Sader, Cecilia G Carvalhaes, Jennifer M Streit, et al.
Diagnostic Microbiology and Infectious Disease|April 15, 2023
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022)Helio S Sader, Rodrigo E Mendes, Leonard Duncan, et al.
International Journal of Antimicrobial Agents|June 14, 2016
Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014)Helio S Sader, Mariana Castanheira, David J Farrell, et al.
The Pediatric Infectious Disease Journal|April 14, 2017
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014Michael A Pfaller, Rodrigo E Mendes, Mariana Castanheira, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2021
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019Rodrigo E Mendes, Timothy B Doyle, Jennifer M Streit, et al.
International Journal of Antimicrobial Agents|May 10, 2015
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumoniaHelio S Sader, Mariana Castanheira, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2016
Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potencyRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Pageof 48

Showing results (261-270 of 473) with videos related to

Sort By:
Pageof 48
Public Health Reports (Washington, D.C. : 1974)|November 1, 1990
Training health professionals and lay volunteers to deliver cholesterol screening and education programsL A Linnan, K M Gans, M L Hixson, et al.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas|August 20, 2010
Lipopolysaccharide-induced expression of cell surface receptors and cell activation of neutrophils and monocytes in whole human bloodN E Gomes, M K C Brunialti, M E Mendes, et al.
Regulatory Toxicology and Pharmacology : RTP|July 30, 2011
Factors affecting exposure to nicotine and carbon monoxide in adult cigarette smokersRaheema Muhammad-Kah, Qiwei Liang, Kimberly Frost-Pineda, et al.
Journal of Global Antimicrobial Resistance|December 7, 2020
Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by speciesHelio S Sader, Cecilia G Carvalhaes, Jennifer M Streit, et al.
Diagnostic Microbiology and Infectious Disease|April 15, 2023
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022)Helio S Sader, Rodrigo E Mendes, Leonard Duncan, et al.
International Journal of Antimicrobial Agents|June 14, 2016
Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014)Helio S Sader, Mariana Castanheira, David J Farrell, et al.
The Pediatric Infectious Disease Journal|April 14, 2017
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014Michael A Pfaller, Rodrigo E Mendes, Mariana Castanheira, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2021
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019Rodrigo E Mendes, Timothy B Doyle, Jennifer M Streit, et al.
International Journal of Antimicrobial Agents|May 10, 2015
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumoniaHelio S Sader, Mariana Castanheira, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2016
Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potencyRodrigo E Mendes, Mariana Castanheira, David J Farrell, et al.
Pageof 48